Pomalidomide, bortezomib and low-dose dexamethasone in lenalidomide-refractory and proteasome inhibitor-exposed myeloma
View/ Open
Author
Richardson, P G
Hofmeister, C C
Raje, N S
Siegel, D S
Lonial, S
Laubach, J
Efebera, Y A
Vesole, D H
Nooka, A K
Rosenblatt, J
Doss, D
Zaki, M H
Bensmaine, A
Herring, J
Li, Y
Watkins, L
Chen, M S
Anderson, K C
Note: Order does not necessarily reflect citation order of authors.
Published Version
https://doi.org/10.1038/leu.2017.173Metadata
Show full item recordCitation
Richardson, P. G., C. C. Hofmeister, N. S. Raje, D. S. Siegel, S. Lonial, J. Laubach, Y. A. Efebera, et al. 2017. “Pomalidomide, bortezomib and low-dose dexamethasone in lenalidomide-refractory and proteasome inhibitor-exposed myeloma.” Leukemia 31 (12): 2695-2701. doi:10.1038/leu.2017.173. http://dx.doi.org/10.1038/leu.2017.173.Abstract
This phase 1 dose-escalation study evaluated pomalidomide, bortezomib (subcutaneous (SC) or intravenous (IV)) and low-dose dexamethasone (LoDEX) in lenalidomide-refractory and proteasome inhibitor-exposed relapsed or relapsed and refractory multiple myeloma (RRMM). In 21-day cycles, patients received pomalidomide (1–4 mg days 1–14), bortezomib (1–1.3 mg/m2 days 1, 4, 8 and 11 for cycles 1–8; days 1 and 8 for cycle ⩾9) and LoDEX. Primary endpoint was to determine the maximum tolerated dose (MTD). Thirty-four patients enrolled: 12 during escalation, 10 in the MTD IV bortezomib cohort and 12 in the MTD SC bortezomib cohort. Patients received a median of 2 prior lines of therapy; 97% bortezomib exposed. With no dose-limiting toxicities, MTD was defined as the maximum planned dose: pomalidomide 4 mg, bortezomib 1.3 mg/m2 and LoDEX. All patients discontinued treatment by data cutoff (2 April 2015). The most common grade 3/4 treatment-emergent adverse events were neutropenia (44%) and thrombocytopenia (26%), which occurred more frequently with IV than SC bortezomib. No grade 3/4 peripheral neuropathy or deep vein thrombosis was reported. Overall response rate was 65%. Median duration of response was 7.4 months. Pomalidomide, bortezomib and LoDEX was well tolerated and effective in lenalidomide-refractory and bortezomib-exposed patients with RRMM.Other Sources
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5729338/pdf/Terms of Use
This article is made available under the terms and conditions applicable to Other Posted Material, as set forth at http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAACitable link to this page
http://nrs.harvard.edu/urn-3:HUL.InstRepos:34651845
Collections
- HMS Scholarly Articles [17921]
Contact administrator regarding this item (to report mistakes or request changes)